This clinical trial is focused on studying a type of breast cancer known as triple-negative breast cancer (TNBC). This form of cancer does not have the three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and HER2. The study is specifically looking at patients with advanced stages of this cancer, either locally advanced, inoperable, or metastatic, meaning it has spread to other parts of the body. The trial involves a medication called sacituzumab govitecan, which is being compared to other treatments chosen by doctors. Sacituzumab govitecan is a type of treatment known as an antibody-drug conjugate, which combines an antibody with a drug to target cancer cells more precisely.

The purpose of the study is to compare the effectiveness of sacituzumab govitecan with other treatments in patients who have not received previous treatment for their advanced cancer or who have been treated with certain immune therapies. The study will involve administering the treatments through an intravenous infusion, which means the medication is given directly into a vein. Patients will be monitored over a period to see how their cancer responds to the treatment. The study will also look at how long patients live and how their quality of life is affected by the treatment.

Participants in the study will receive either sacituzumab govitecan or a treatment chosen by their doctor, which may include medications like paclitaxel, gemcitabine, or carboplatin. These are all chemotherapy drugs that work by stopping the growth of cancer cells. The study aims to provide more information on the best treatment options for patients with this challenging type of breast cancer. The trial is expected to continue until 2027, allowing researchers to gather comprehensive data on the effectiveness and safety of the treatments being studied.